FR06C0024I1 - - Google Patents
Info
- Publication number
- FR06C0024I1 FR06C0024I1 FR06C0024C FR06C0024I1 FR 06C0024 I1 FR06C0024 I1 FR 06C0024I1 FR 06C0024 C FR06C0024 C FR 06C0024C FR 06C0024 I1 FR06C0024 I1 FR 06C0024I1
- Authority
- FR
- France
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18626994A | 1994-01-25 | 1994-01-25 | |
| PCT/US1995/001219 WO1995019790A1 (en) | 1994-01-25 | 1995-01-25 | Humanized antibodies against leukocyte adhesion molecule vla-4 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR06C0024I1 true FR06C0024I1 (enrdf_load_stackoverflow) | 2006-10-13 |
| FR06C0024I2 FR06C0024I2 (fr) | 2009-01-02 |
Family
ID=22684288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR06C0024C Active FR06C0024I2 (fr) | 1994-01-25 | 2006-07-27 | Anticorps humanises diriges contre la molecule d'adhesion leucocytaire vla-4 |
Country Status (21)
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6307025B1 (en) | 1989-04-28 | 2001-10-23 | Biogen, Inc. | VCAM fusion proteins and DNA coding therefor |
| US5871734A (en) * | 1992-01-13 | 1999-02-16 | Biogen, Inc. | Treatment for asthma with VLA-4 blocking agents |
| US5932214A (en) | 1994-08-11 | 1999-08-03 | Biogen, Inc. | Treatment for inflammatory bowel disease with VLA-4 blockers |
| ATE182625T1 (de) | 1993-01-12 | 1999-08-15 | Biogen Inc | Rekombinante anti-vla4 antikörpermoleküle |
| EP0682529B2 (en) * | 1993-02-09 | 2005-12-28 | Biogen Idec MA, Inc. | Antibody for the treatment of insulin dependent diabetes |
| US7435802B2 (en) | 1994-01-25 | 2008-10-14 | Elan Pharaceuticals, Inc. | Humanized anti-VLA4 immunoglobulins |
| US5840299A (en) * | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| US7750137B2 (en) | 1995-09-01 | 2010-07-06 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressins |
| US7803904B2 (en) | 1995-09-01 | 2010-09-28 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressing and uses thereof |
| US6551593B1 (en) | 1995-02-10 | 2003-04-22 | Millennium Pharmaceuticals, Inc. | Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam |
| US7147851B1 (en) * | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| AU7348798A (en) * | 1997-05-09 | 1998-12-08 | John P. Robarts Research Institute, The | Method for dislodging infiltrated leukocytes from a tissue |
| DE19741235A1 (de) | 1997-09-18 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| DE19741873A1 (de) * | 1997-09-23 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| DE19751251A1 (de) | 1997-11-19 | 1999-05-20 | Hoechst Marion Roussel De Gmbh | Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate |
| DE19821483A1 (de) | 1998-05-14 | 1999-11-18 | Hoechst Marion Roussel De Gmbh | Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| EE05558B1 (et) * | 1998-09-14 | 2012-08-15 | Board Of Regents, The University Of Texas System | Antikeha v?i selle antigeeni siduva fragmendi v?i lahustuva polpeptiidi kasutamine farmatseutilise kompositsiooni valmistamiseks |
| US7618630B2 (en) | 1998-09-14 | 2009-11-17 | Board Of Regents, The University Of Texas System | Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists |
| MXPA01010612A (es) | 1999-04-22 | 2003-09-04 | Biogen Inc | Metodo para el tratamiento de fibrosis usando un antagonista de la subunidad alfa-4 integrina. |
| DE19922462A1 (de) | 1999-05-17 | 2000-11-23 | Aventis Pharma Gmbh | Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| EA011384B1 (ru) | 1999-06-01 | 2009-02-27 | Байоджен Айдек Ма Инк. | Способ лечения воспалительного заболевания |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| EP2332578A1 (en) * | 1999-12-16 | 2011-06-15 | Biogen Idec MA Inc. | Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists |
| DE10111877A1 (de) | 2001-03-10 | 2002-09-12 | Aventis Pharma Gmbh | Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| HUP0402250A3 (en) | 2001-04-13 | 2007-06-28 | Biogen Idec Inc | Antibodies to vla-1 |
| DE10137595A1 (de) | 2001-08-01 | 2003-02-13 | Aventis Pharma Gmbh | Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung |
| CA2477178A1 (en) * | 2002-02-25 | 2003-09-04 | Elan Pharmaceuticals, Inc. | Administration of agents for the treatment of inflammation |
| JP2005535572A (ja) * | 2002-04-12 | 2005-11-24 | メディミューン，インコーポレーテッド | 組換え抗インターロイキン−９抗体 |
| GB0210121D0 (en) * | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
| TWI323265B (en) * | 2002-08-06 | 2010-04-11 | Glaxo Group Ltd | Antibodies |
| EP1572748B1 (en) * | 2002-12-17 | 2010-06-23 | MERCK PATENT GmbH | Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2 |
| CU23403A1 (es) * | 2003-04-23 | 2009-08-04 | Centro Inmunologia Molecular | Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores |
| BRPI0418026A (pt) | 2003-12-22 | 2007-04-17 | Ajinomoto Kk | derivados de fenilalanina ou sais farmaceuticamente aceitáveis destes, composição farmacêutica, antagonista de alfa4 integrina, e, agente terapêutico ou agente preventivo para doenças |
| CN101102792A (zh) * | 2004-11-19 | 2008-01-09 | 比奥根艾迪克Ma公司 | 治疗多发性硬化 |
| CA2629147A1 (en) * | 2005-11-17 | 2007-05-31 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with .alpha.4.beta.7 integrin |
| PT2034830E (pt) | 2006-05-25 | 2014-10-14 | Biogen Idec Inc | Anticorpos anti-vla-1 para o tratamento de acidentes vasculares cerebrais |
| EP2510941A3 (en) | 2007-02-20 | 2013-01-23 | Merrimack Pharmaceuticals, Inc. | Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist |
| NZ595526A (en) * | 2007-06-14 | 2013-03-28 | Biogen Idec Inc | Pharmaceutical composition comprising a vla-4 binding antibody, a phosphate buffer and a surfactant |
| BRPI0820202B1 (pt) | 2007-12-13 | 2018-05-08 | Tokuyama Corp | composição curável fotocrômica |
| KR20110008086A (ko) | 2008-04-11 | 2011-01-25 | 메리맥 파마슈티컬즈, 인크. | 인간 혈청 알부민 링커 및 그 콘쥬게이트 |
| CN103382222B (zh) | 2009-03-20 | 2016-12-28 | 安姆根有限公司 | α-4-β-7异二聚体特异性拮抗剂抗体 |
| WO2011020874A1 (en) | 2009-08-20 | 2011-02-24 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy |
| ES2805873T3 (es) | 2010-04-16 | 2021-02-15 | Biogen Ma Inc | Anticuerpos anti-VLA-4 |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| KR102136208B1 (ko) | 2011-05-02 | 2020-07-21 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 항-α4β7 항체에 대한 제형 |
| CA2864539C (en) | 2012-02-16 | 2022-06-07 | Santarus, Inc. | Antibody formulations |
| US20190225694A1 (en) | 2016-06-28 | 2019-07-25 | Zaklady Farmaceutyczne Polpharma Sa | Recombinant production of monoclonal antibodies |
| WO2018091729A2 (en) | 2016-11-21 | 2018-05-24 | Zaklady Farmaceutyczne Polpharma Sa | Aqueous pharmaceutical formulations |
| CN110997714B (zh) * | 2017-02-17 | 2024-05-03 | 赛诺菲 | 对肌营养不良蛋白聚糖和层粘连蛋白-2具有特异性的多特异性结合分子 |
| US12043845B2 (en) | 2017-06-08 | 2024-07-23 | Polpharma Biologics S.A. | Methods of cell culture |
| KR102848349B1 (ko) | 2018-06-04 | 2025-08-21 | 바이오젠 엠에이 인코포레이티드 | 감소된 효과기 기능을 갖는 항-ｖｌａ-4 항체 |
| WO2022162164A1 (en) | 2021-01-29 | 2022-08-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| IL162181A (en) * | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| IL113261A (en) * | 1989-09-01 | 1996-10-16 | Hutchinson Fred Cancer Res | Inhibition by peptides of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction and pharmaceutical compositions containing said peptides |
| DE69309906T2 (de) * | 1992-02-12 | 1997-11-06 | Biogen, Inc., Cambridge, Mass. | Behandlung für entzündungserkrankung des darmes |
| ATE182625T1 (de) * | 1993-01-12 | 1999-08-15 | Biogen Inc | Rekombinante anti-vla4 antikörpermoleküle |
| AUPP647298A0 (en) | 1998-10-13 | 1998-11-05 | Keystone Retaining Wall Systems, Inc. | Retaining wall block |
-
1995
- 1995-01-25 AT AT95908741T patent/ATE333895T1/de active
- 1995-01-25 EP EP95908741A patent/EP0804237B8/en not_active Expired - Lifetime
- 1995-01-25 CA CA002182013A patent/CA2182013C/en not_active Expired - Lifetime
- 1995-01-25 PL PL95315634A patent/PL181827B1/pl unknown
- 1995-01-25 PT PT95908741T patent/PT804237E/pt unknown
- 1995-01-25 KR KR1019960703987A patent/KR100367948B1/ko not_active Expired - Lifetime
- 1995-01-25 ES ES95908741T patent/ES2270425T3/es not_active Expired - Lifetime
- 1995-01-25 AU AU16960/95A patent/AU703152B2/en not_active Expired
- 1995-01-25 CN CNB951913549A patent/CN1211123C/zh not_active Expired - Lifetime
- 1995-01-25 WO PCT/US1995/001219 patent/WO1995019790A1/en active IP Right Grant
- 1995-01-25 DE DE69535133T patent/DE69535133T2/de not_active Expired - Lifetime
- 1995-01-25 DE DE1995635133 patent/DE122006000043I1/de active Pending
- 1995-01-25 DK DK95908741T patent/DK0804237T3/da active
- 1995-01-25 HU HU9602019A patent/HU220799B1/hu active Protection Beyond IP Right Term
- 1995-01-25 EP EP06013916A patent/EP1759709B1/en not_active Expired - Lifetime
- 1995-01-25 NZ NZ279730A patent/NZ279730A/en not_active IP Right Cessation
- 1995-01-25 DK DK06013916.9T patent/DK1759709T3/da active
- 1995-01-25 ES ES06013916T patent/ES2424292T3/es not_active Expired - Lifetime
- 1995-01-25 JP JP51977095A patent/JP4115517B2/ja not_active Expired - Lifetime
-
1996
- 1996-07-24 MX MX9602971A patent/MX9602971A/es unknown
- 1996-07-24 NO NO19963097A patent/NO319867B1/no not_active IP Right Cessation
- 1996-07-24 FI FI962958A patent/FI117509B/fi active Protection Beyond IP Right Term
-
2005
- 2005-08-05 JP JP2005228930A patent/JP2006045237A/ja not_active Withdrawn
-
2006
- 2006-07-27 FR FR06C0024C patent/FR06C0024I2/fr active Active
- 2006-08-02 LU LU91271C patent/LU91271I2/fr unknown
- 2006-08-02 NL NL300238C patent/NL300238I2/nl unknown
- 2006-08-07 NO NO2006008C patent/NO2006008I2/no unknown
-
2009
- 2009-05-18 JP JP2009120421A patent/JP2009235078A/ja not_active Withdrawn
-
2013
- 2013-02-18 JP JP2013028635A patent/JP5487382B2/ja not_active Expired - Lifetime
- 2013-03-18 JP JP2013054628A patent/JP2013165718A/ja not_active Withdrawn
-
2017
- 2017-08-01 NO NO2017040C patent/NO2017040I2/no unknown